INTRODUCTION
Manipulative genetic tools in the mouse are extensive and powerful. Mouse geneticists can eliminate or overexpress genes in the whole animal or in a specific tissue, introduce large pieces of self or foreign DNA into the genome and engineer whole chromosomes. These techniques, combined with the genetic, developmental, pathologic and physiologic similarities between mouse and human, have established the laboratory mouse as a primary model organism for human disease research. Inbred strains of mice provide the opportunity to study a disease trait in a defined genetic background, allowing distinction between the phenotypes conferred by a single mutation versus the contributions of other genetic modifiers.
The ability to engineer loss of function mutations by homologous recombination in embryonic stem cells pioneered a revolution in mouse biology. Using embryonic stem cell technology, any gene involved in human disease can be disrupted, providing valuable information about the consequences of mutation in the whole animal. While null mutations are necessary, subtle mutations induced by N-ethyl-N-nitrosourea (ENU) are invaluable for examining the full range of gene function. Mutations in coding regions and regulatory elements can yield vastly different phenotypes while they provide a fine-structure dissection of protein function and gene regulation. Series of alleles may be generated by homologous recombination, but phenotypedriven mutagenesis offers many advantages in speed of generation and removal of investigator bias. Therefore, a knockout database for the mouse genome should be considered only as a starting point; additional alleles and tissue specificities are mandatory to complete the functional analysis.
MUTAGENIZING THE MOUSE GERMLINE
ENU can transfer its ethyl group to oxygen or nitrogen radicals in DNA, resulting in mispairing and base-pair substitution if not repaired. The highest mutation rates occur in pre-meiotic spermatogonial stem cells, with single locus mutation frequencies of 6-1.5 × 10 -3 (1-3), equivalent to obtaining a mutation in a single gene of choice in one out of every 175-655 gametes screened. Because of its power in isolating mutations in any gene or region of interest, ENU has been used in the mouse to: (i) obtain multiallelic series of single genes to further define function; (ii) dissect biochemical or developmental pathways; (iii) obtain new recessive mutations on a single chromosome or genome-wide; and (iv) saturate regions of the mouse genome that are uncovered by deletions (4) (5) (6) (7) (8) (9) (10) . The analysis of 62 sequenced germline mutations from 24 genes reveals that ENU predominantly modifies A/T base pairs, with 44% A/T→T/A transversions, 38% A/T→G/C transitions, 8% G/C →A/T transitions, 3% G/C→C/G transversions, 5% A/T→C/G transitions and 2% G/C→T/A transitions (Table 1 ; Fig. 1 ). When translated into a protein product, these changes result in 64% missense mutations, 10% nonsense mutations and 26% splicing errors (Table 1 ; Fig. 1 ).
Because it is a point mutagen, ENU can induce many different types of allele. Loss-of-function mutations, viable hypomorphs of lethal complementation groups, antimorphs and gain-of-function mutations have been isolated in mouse mutagenesis screens (4, (9) (10) (11) (12) (13) (14) (15) (16) . Series of alleles at single loci are extremely powerful when analyzed together to define function. Allelic series at complex loci can disrupt individual protein isoforms, leading to the discovery of distinct functions in various tissues throughout the life of an organism (17) . A striking example of such an allelic series is the quaking (qk) locus. Prior to the isolation of the ENU-induced alleles, the quaking locus was defined by a single spontaneous allele, qk v , with a homozygous phenotype of seizures and quaking caused by severe central nervous system (CNS) dysmyelination (18) . The ENU-induced alleles, however, reveal that quaking also functions during embryogenesis (7, 13) . Homozygotes of four of five ENU-induced alleles (qk l-1 , qk kt1 , qk k2 , qk kt3/4 ) die at embryonic days (E) 8.5-10.5 with CNS defects, whereas only one is viable with quaking and seizures (qk e5 ) (19; J.K. Noveroske and M.J. Justice, unpublished data). Although the quaking alleles can be grouped based on embryo lethality or viable dysmyelination, each allele deviates in some significant way from these general phenotypes to make it a unique and valuable resource for fine-structure/function studies and modeling human neural tube defects, as well as seizure and myelination disorders (Table 2 ). Allelic series generated by The number of mutations induced by ENU and those that have been sequenced are shown in columns 2 and 3. The number of lesions of each type are shown in column 4; these do not correlate with the functional change in column 5. Note that the lesion was not found in two of the mutations listed as splice mutations, so these two are not included in the numbers given in the text. ?, the number of ENU-induced mutations is not known. ENU or gene targeting at other complex loci will be valuable tools for dissecting protein function (17) .
ISOLATING DISEASE MODELS USING ENU
Different genetic screens can be used to isolate ENU-induced mutations. A single generation screen can rapidly generate viable and fertile mutants that represent allele series, modifiers or dominant mutations. Two-generation deletion screens can identify recessive lethal mutations in a defined region of the genome. Three-generation pedigree screens may be used to scan the entire genome for a viable mutation of interest or, in combination with linked markers or balancer chromosomes, to isolate lethal or sterile alleles (see below).
Large-scale screens
Several large-scale mutagenesis screens have already been funded internationally. The key features of these screens are summarized in Table 3 . Each of these screens uses a different genetic strategy to isolate mutations: some screens target dominant mutations, whereas others are designed to isolate recessive mutations. Some groups are screening for recessive lethal and detrimental mutations with regional mutagenesis to address gene function in parallel with the Human Genome Project. Other groups are scanning large numbers of mutagenized genomes for dominant neurological and clinical hematology or biochemical variants.
Small-scale screens
Screening for mutations does not have to be carried out on a large scale. Two cost-effective strategies for the small laboratory are allelic series and sensitized pathway screens. A sensitized pathway screen targets a single biological or biochemical pathway, and exploits non-allelic non-complementation to isolate mutations in the first generation offspring of mutagenized males. In such a screen, an induced mutation (*) at a locus that interacts with the locus of interest (m) may fail to complement (*/+;+/m), yet yield a phenotype reminiscent of the original homozygous mutant (m/m). Some sensitized screens may be carried out in the background of a drug or environmental modification, instead of a genetic modification. For example, using a phenylalanine injection as a sensitizer, a number of mutations affecting the phenylalanine metabolism pathway were isolated as heterozygotes (20, 21) .
Combining gene-driven and phenotype-driven approaches
A unique approach towards isolating mutations combines genebased targeting in embryonic stem cells with phenotype-driven ENU mutagenesis. Powerful genetic strategies in Drosophila rely on the availability of genetic reagents such as deletions, duplications and inversions to facilitate genetic screens and provide simple, cost-effective stock maintenance. Deletions are useful for generating haploidy in genetic screens, as well as for mapping using non-complementation strategies ( Fig. 2B ) (22) . Inversions that carry a dominant marker and are homozygous lethal are ideal balancer chromosomes to suppress recombination These lesions are present in the sperm of the male, and after their isolation through genetic and phenotypic screens, give rise to a variety of phenotypic mutations. The mutant protein products are primarily missense mutations, a valuable class of mutations for dissecting protein structure and function. Mutagenesis in the mouse will emphasize modeling human diseases through phenotype-driven assays. and readily identify classes of offspring for the isolation and maintenance of lethal or detrimental mutations (Fig. 2C) . The ability to engineer whole chromosome regions using Cre/loxP technologies allows the creation of these genetic reagents in a twostep gene targeting process ( Fig. 2A) (23,24) . The approach is gene-based because the endpoints of the deletion or inversion are known, minimizing the amount of effort required to characterize the rearrangements. Engineering techniques allow for the rearrangements to be tagged with a dominant yellow coat color marker, K-14 agouti, providing a resource for simple mapping, stock maintenance and genetic screens (22, 24, 25) . The creation of mouse genomic libraries containing the constructs necessary for the targeting events provides a rapid system for their generation anywhere in the mouse genome ( Fig. 2A ) (25) . An initial mutagenesis effort, designed to isolate recessive mutations of many phenotypic classes, is targeting mouse Chromosome 11, which is a gene rich chromosome highly conserved with human Chromosome 17. The goal is to saturate the chromosome with mutations to define gene function, then use linkage conservation between the mouse and human to predict gene function in the human. Using the genetic reagents generated by Cre/loxP engineering, two mutagenesis schemes are being carried out: two-generation deletion pedigrees (Fig. 2B ) and threegeneration pedigrees using balancer chromosomes (Fig. 2C) . Both schemes take advantage of the yellow coat color conferred by the K14-agouti transgene. The deletion scheme can be used only for large deletions that are not detrimental to the animal, limiting the screen to certain regions, but allowing mutations to be isolated in only two generations. The inversion scheme allows a larger portion of the chromosome to be screened for mutations, but requires three generations of breeding.
IDENTIFYING POINT MUTATIONS
To be valuable, new mutations must be localized so that candidate genes and relevant human disease models can be identified. Point mutations isolated by their phenotype must be mapped using phenotype information, since a molecular tag is not available. Traditionally, these mutations are mapped in meiotic backcrosses segregating the phenotype relative to multiple molecular polymorphisms (for a review see ref. 26) . To map to a resolution of 10 cM requires analyzing 100 meioses. Thus, 100 new mutations isolated genome-wide would require the analysis of 10 000 mice. High resolution mapping strategies for positional cloning usually involve the analysis of 1000-2000 meioses per mutation. A multitude of dominant and recessive mutations can be isolated in any ENU screen, making mapping the bottleneck in the process, and requiring simpler mapping technologies such as DNA pooling (27) . The coat color tagged screens described above are unique in that the mutation is isolated linked to visible chromosomal markers, so its chromosome location is known upon isolation, eliminating the need for meiotic mapping. Furthermore, the Cre/loxP generated deletions can be used to localize the mutations to a sub-chromosomal region by non-complementation (22, 28) . Because the sequence of the mouse genome will soon be available, many mutations will be assigned to genes based on positional candidacy after their localization. In addition, BAC complementation can be used to identify mutation-gene correlations (29) .
As new technologies are being developed for high-throughput single nucleotide polymorphism detection, technologies for the detection of point mutations will become simpler (30, 31) . Unlike humans, naturally occurring polymorphisms are rare in inbred strains of mice, in particular within coding regions. Thus, the detection of point mutations is possible in an inbred strain background, making mutation detection with mismatch repair enzymes a potential approach to quickly map and identify the lesions.
SCREENING FOR DISEASE PHENOTYPES
In any screen for mutations using ENU, mutation isolation relies upon the phenotype assay, requiring that the mutant phenotype must vary significantly from the background. However, screening for mutations involves the analysis of many animals, so phenotype screens must be broad and inexpensive. Visible phenotypes that affect the eye, coat, size or neurological behavior are simple to identify, and such screens often yield novel mutations. Behavior and sensory organ phenotypes can be screened for using standard tests for reflex, sight or hearing loss, motor development, balance The deletion or inversion is tagged with a dominant yellow coat color marker, K-14-agouti (yellow). Each scheme uses the dominant Rex (Re, and indicated by the black chromosome) mutation on Chr 11, which causes curly fur (mottled). In each scheme, wild-type males (C57BL/6J, black) are injected with a 3 × 100 mg/kg dose of ENU. (B) The deletion scheme. After regaining fertility, ENU-treated males are mated to homozygous Re/Re females. The Re mutation marks the non-mutagenized chromosome, with the caveat that recombination can occur between a new linked mutation and Re. G1 animals, heterozygous for ENU mutagenized chromosomes and Re are mated to mice hemizygous for a yellow-tagged deletion. The resulting classes of offspring can be readily identified: (i) the mutant class is yellow and straight-haired and, if missing, indicates the likelihood of a lethal mutation; (ii) a carrier class that is wild-type, and can be used to recover any lethal mutations; (iii) two curly-haired classes of mice (black and yellow) that are uninformative and can be immediately discarded. (C) The inversion scheme. The balancer chromosome contains an inversion that suppresses recombination over a reasonable interval, 20-30 cM, is marked with the dominant K14-agouti transgene conferring yellow coat color, and is homozygous lethal due to disruption of one or more lethal genes at its endpoints. After regaining fertility, ENU-treated males are mated to females carrying the balancer chromosome (yellow). G1 animals that are yellow are mated with animals heterozygous for the balancer chromosome and Re (yellow mottled). Three classes of offspring can be identified in the second generation, and the fourth class, which is homozygous for the balancer chromosome, dies (upside down). The useful G2 animals are the yellow, straight-haired animals, which are brother-sister mated. The G3 offspring are easily classified as: (i) the wild-type mutant class, which if missing indicates the likelihood of a linked lethal mutation and (ii) a carrier class used to rescue any lethal mutations, which carries the balanced point mutation, ideal for stock maintenance. and coordination, as well as learning and memory. Skeletal development and soft tissue morphology can be examined using high resolution, low energy X-ray analysis. Clinical tests performed on mouse blood can yield a vast array of phenotypes relevant to human clinical disease even though tests performed on mouse body fluids must be performed on a microscale. Because of existing microscale tests for human infants, many clinical tests are already available. A complete blood count with microscopic differential analysis can identify abnormalities in red blood cell and white blood cell numbers or morphology, as well as platelet abnormalities. Extending the analysis of blood cells with flow cytometry may uncover other immunological defects. Antinuclear antibody quantitation can detect serum autoantibodies in a large variety of autoimmune disorders, including systemic lupus erythematosus. Clinical chemistry tests can diagnose multiple organ system anomalies, including liver, pancreatic, heart and kidney disorders. Urinalysis on mice reveals increased levels of protein or other abnormal by-products of disease. Tandem mass spectrometry can detect a variety of metabolic disorders affecting lipids, fatty acids or amino acids. Additional assays are being developed to identify neurological, cardiovascular, hematopoietic and immune phenotypes using high-throughput technologies such as microarrays.
GENERATING RESOURCES FOR MUTANT MICE
The generation of large numbers of mutations will create new ethical and scientific issues within the mouse community: new databases and phenotype assays will be required, cost effective mutation recovery from cryopreserved or freeze-dried sperm will become essential, and animal care and cost issues will arise. These efforts require a tremendous investment in mouse resources.
Genetic resources
One of the most powerful genetic resources currently available in the mouse are the inbred strains. Further defining genetic diversity in these strains is one of the priorities of the mouse community, with efforts underway to develop a strain characteristics database. This requires analyzing the inbred strains for many phenotypic parameters, including clinical hematology and chemistry, pathology, behavior and physiology.
The maintenance, analysis and mapping of large numbers of mouse mutations will require the generation of genetic resources to lower costs and reduce mistakes. Genetic reagents such as deletions are being developed by a variety of methods including Cre/loxP and radiation (22, 23, 25, 32, 33) . Balancer chromosomes can currently be generated quickly and efficiently using Cre/loxP approaches (24, 25) . Transgenic mice containing human YACs or BACs can be useful in complementation and rescue studies (34) . Because mutant phenotypes can vary on different inbred strain backgrounds, genetic reagents should also be maintained on standard genetic backgrounds.
Archiving
The generation of large numbers of mouse stocks requires efficient archiving and reconstitution of stocks. Storing mouse embryos by cryopreservation is an effective technique that has already been used for over a decade. Recently, successes in sperm cryopreservation have made it a tractable technique (35) (36) (37) . In particular, mouse sperm can be used to reconstitute stocks by a number of assisted reproductive technologies: artificial insemination, in vitro fertilization and intracytoplasmic sperm injection (ICSI) (38) . The successful reconstitution of mouse strains from freeze-dried sperm using ICSI may provide another method for archiving and reviving mouse strains (39) .
Databases
Databases are already required for handling mouse genetic and phenotypic data. The primary mouse database is the Mouse Genome Database housed at the Jackson Laboratory (Bar Harbor, ME; http://www.informatics.jax.org ), which includes a Mouse Locus Catalogue describing existing mouse mutants, and containing extensive map information describing their locations. To simplify the search for mutant mice, the International Mouse Strain Resource has recently been developed (40) , which is mirrored at two Web sites: the Jackson Laboratory at http:// www.jax.org/pub-cgi/imsrlist and the MRC, Harwell, at http:// imsr.har.mrc.ac.uk/ . In addition, large amounts of phenotype data are likely to accumulate on large numbers of mutant mouse strains, creating the need for phenotype databases that can be linked with mapping and mutagenesis databases.
Distribution
To provide a genetic resource to the community, mutant mice must be readily available. Although many mutant stocks are available from commercial vendors or from the Jackson Laboratory, additional distribution centers are required. To meet this demand, several NIH-funded Mutant Mouse Resource Centers will serve as stock archives and distribution centers for the various regions of the USA. The European Mutant Mouse Archive with nodes in Monteretondo (Roma, Italy), the CNRS (Orleans, France), the Gulbenkian Institute (Lisbon, Portugal) and the Karolinska Institute (Huddings, Sweden) is a resource for the European efforts. These resource centers are designed to distribute all types of mutant mouse strain.
THE FUTURE LOOKS BRIGHT
A large number of mutant mouse stocks will be generated over the next decade that will include mice carrying deletions, duplications, balancer chromosomes, targeted disruptions, gene trap, retroviral or transgenic insertions, and point mutations. The compilation of these mutations into a mutant mouse resource will require refining their map locations in the mouse and predicting their locations in the human. The mutations will generate a functional map of the genome that can be correlated with the sequence and transcript map to provide a rich resource of functional information (Fig. 3) . A large number of ENU-induced Figure 3 . A mutant mouse resource. Initially, a mutant mouse resource at Baylor College of Medicine will be developed for mouse chromosome 11, and is used here as a demonstration of the types of genetic resource that will be available in the mouse. Ideally, such resources will be developed for other mouse chromosomes. The mutant resource will consist of a variety of mutations, including point mutations induced by ENU, targeted gene disruptions and insertions, as well as genetic reagents such as deletions and inversions. These mutations will constitute a functional map of the chromosome, and will be localized in molecular intervals, so they can be anchored to the physical map consisting of BAC and YAC contigs. When the mouse genome is sequenced, the mutations can be correlated with candidate genes that lie within the molecular intervals.
Downloaded from https://academic.oup.com/hmg/article-abstract/8/10/1955/620762 by guest on 28 February 2019 mutations have already been produced that represent only a fraction of the mutational potential of the mammalian genome, and additional experiments will generate new human disease models and reveal new mammalian developmental pathways. Our view of gene function in mammals will be dramatically and permanently changed by these experiments, which will greatly impact drug development and human health.
